Teva Completes $13.5 Million Investment in Andromeda, Gaining Exclusive Rights to Commercialize DiaPep277

Strategic Insights -

Teva Pharmaceutical Industries Ltd. has completed a $13.5 million investment in Andromeda Biotech Ltd., securing a worldwide exclusive license to commercialize DiaPep277, a potential treatment for Type 1 diabetes. The investment marks a significant milestone in the development of DiaPep277, which is currently in Phase III clinical studies. This move will accelerate the product's launch and provide Teva with a significant market share in the treatment of Type 1 diabetes.

Key Takeaways:

  • Teva Pharmaceutical Industries Ltd. has completed a $13.5 million investment in Andromeda Biotech Ltd., gaining exclusive rights to commercialize DiaPep277.
  • DiaPep277 is a potential treatment for Type 1 diabetes, which affects approximately 1% of the world's population.
  • The investment will fund the completion of a Phase III study, with results expected to be announced soon.
  • Andromeda's DiaPep277 has the potential to address the significant unmet medical need for a treatment for Type 1 diabetes, with an estimated potential market of over half a billion dollars per year.
  • Teva now has a significant stake in the development and commercialization of DiaPep277, with worldwide marketing rights for the product.
  • The partnership between Teva and Andromeda will accelerate the development of DiaPep277 and provide a potential solution for millions of people affected by Type 1 diabetes.

Statistics:

  • $13.5 million - The amount invested by Teva in Andromeda Biotech Ltd.
  • 1% - The percentage of the population affected by Type 1 diabetes.
  • 40 - The number of medical centers participating in the Phase III study of DiaPep277.
  • Over half a billion dollars - The estimated market potential for DiaPep277.
  • 5 years - The maximum duration of the license agreement between Teva and Andromeda.

Sources:

  • "Teva Completes $13.5 million Investment in Andromeda and Receives Exclusive Rights to Commercialize DiaPep277" - Andromeda Biotech Ltd. (www.andromedabio.com)
  • "Type 1 Diabetes" - Andromeda Biotech Ltd. (www.andromedabio.com)
  • NewsRx.com - "Diabetes Week Via" (2009)